Comments
Loading...

ACADIA Pharmaceuticals

ACADNASDAQ
$18.48
0.291.59%
At Close: -
$18.60
0.120.65%
After Hours: 6:04 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$42.00
Lowest Price Target1
$19.00
Consensus Price Target1
$28.57

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock, Analyst Ratings, Price Targets, Forecasts

ACADIA Pharmaceuticals Inc has a consensus price target of $28.57 based on the ratings of 23 analysts. The high is $42 issued by Cantor Fitzgerald on August 22, 2023. The low is $19 issued by Oppenheimer on May 6, 2024. The 3 most-recent analyst ratings were released by Morgan Stanley, BMO Capital, and RBC Capital on July 12, 2024, June 27, 2024, and June 25, 2024, respectively. With an average price target of $29.33 between Morgan Stanley, BMO Capital, and RBC Capital, there's an implied 57.71% upside for ACADIA Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
7
2
Mar
2
Apr
2
2
May
2
Jun
1
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
BMO Capital
RBC Capital
B of A Securities
Needham

1calculated from analyst ratings

Analyst Ratings for ACADIA Pharmaceuticals

Buy NowGet Alert
07/12/2024Buy Now50.54%Morgan Stanley
Jeffrey Hung
$30 → $28MaintainsOverweightGet Alert
06/27/2024Buy Now66.67%BMO Capital
Keith Tapper
→ $31Initiates → OutperformGet Alert
06/25/2024Buy Now55.91%RBC Capital
Gregory Renza
$29 → $29ReiteratesOutperform → OutperformGet Alert
05/10/2024Buy Now18.28%B of A Securities
Tazeen Ahmad
$26 → $22MaintainsNeutralGet Alert
05/09/2024Buy Now61.29%Needham
Ami Fadia
→ $30ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now98.92%Cantor Fitzgerald
Charles Duncan
→ $37ReiteratesOverweight → OverweightGet Alert
05/09/2024Buy Now45.16%HC Wainwright & Co.
Andrew Fein
$33 → $27MaintainsBuyGet Alert
05/09/2024Buy Now61.29%Citigroup
David Hoang
$30.19 → $30MaintainsBuyGet Alert
05/09/2024Buy Now12.9%Stifel
Paul Matteis
$26 → $21MaintainsHoldGet Alert
05/09/2024Buy Now12.9%Mizuho
Uy Ear
$25 → $21MaintainsNeutralGet Alert
05/09/2024Buy Now50.54%Baird
Joel Beatty
$31 → $28MaintainsOutperformGet Alert
05/06/2024Buy Now2.15%Oppenheimer
Jay Olson
$19 → $19MaintainsPerformGet Alert
04/30/2024Buy Now98.92%Cantor Fitzgerald
Charles Duncan
→ $37ReiteratesOverweight → OverweightGet Alert
04/10/2024Buy Now98.92%Cantor Fitzgerald
Charles Duncan
→ $37ReiteratesOverweight → OverweightGet Alert
04/09/2024Buy Now72.04%Needham
Ami Fadia
→ $32ReiteratesBuy → BuyGet Alert
03/25/2024Buy Now34.41%JP Morgan
Tessa Romero
$29 → $25MaintainsOverweightGet Alert
03/13/2024Buy Now61.29%Morgan Stanley
Jeffrey Hung
$40 → $30MaintainsOverweightGet Alert
03/12/2024Buy Now62.31%Citigroup
David Hoang
$38 → $30.19MaintainsBuyGet Alert
03/12/2024Buy Now61.29%RBC Capital
Gregory Renza
$35 → $30MaintainsOutperformGet Alert
03/12/2024Buy Now34.41%Mizuho
Uy Ear
$39 → $25DowngradeBuy → NeutralGet Alert
03/12/2024Buy Now109.68%JMP Securities
Jason Butler
$44 → $39MaintainsOutperformGet Alert
03/12/2024Buy Now98.92%Cantor Fitzgerald
Charles Duncan
$42 → $37MaintainsOverweightGet Alert
03/12/2024Buy Now66.67%Baird
Joel Beatty
$40 → $31MaintainsOutperformGet Alert
03/12/2024Buy Now2.15%Oppenheimer
Jay Olson
$25 → $19MaintainsPerformGet Alert
03/12/2024Buy Now61.29%B of A Securities
Tazeen Ahmad
$33 → $30MaintainsNeutralGet Alert
03/12/2024Buy Now77.42%Canaccord Genuity
Sumant Kulkarni
$40 → $33MaintainsBuyGet Alert
03/12/2024Buy Now77.42%HC Wainwright & Co.
Andrew Fein
→ $33ReiteratesBuy → BuyGet Alert
03/12/2024Buy Now72.04%Needham
Ami Fadia
$36 → $32MaintainsBuyGet Alert
03/01/2024Buy Now55.91%JP Morgan
Tessa Romero
$32 → $29MaintainsOverweightGet Alert
02/28/2024Buy Now77.42%HC Wainwright & Co.
Andrew Fein
→ $33ReiteratesBuy → BuyGet Alert
02/28/2024Buy Now125.81%Cantor Fitzgerald
Charles Duncan
→ $42ReiteratesOverweight → OverweightGet Alert
02/28/2024Buy Now88.17%RBC Capital
Gregory Renza
$36 → $35MaintainsOutperformGet Alert
02/28/2024Buy Now109.68%Mizuho
Uy Ear
$40 → $39MaintainsBuyGet Alert
02/28/2024Buy Now93.55%Needham
Ami Fadia
$37 → $36MaintainsBuyGet Alert
02/07/2024Buy Now125.81%JMP Securities
Jason Butler
→ $42ReiteratesMarket Outperform → Market OutperformGet Alert
02/05/2024Buy Now34.41%Oppenheimer
Jay Olson
→ $25ReiteratesPerform → PerformGet Alert
02/02/2024Buy Now125.81%Cantor Fitzgerald
Charles Duncan
→ $42ReiteratesOverweight → OverweightGet Alert
01/30/2024Buy Now115.05%Baird
Joel Beatty
→ $40Initiates → OutperformGet Alert
01/24/2024Buy Now98.92%Needham
Joseph Stringer
→ $37UpgradeHold → BuyGet Alert
12/29/2023Buy Now115.05%Mizuho
Uy Ear
$35 → $40MaintainsBuyGet Alert
12/19/2023Buy Now115.05%Morgan Stanley
Jeffrey Hung
$31 → $40UpgradeEqual-Weight → OverweightGet Alert
12/18/2023Buy Now45.16%Stifel
Paul Matteis
$25 → $27MaintainsHoldGet Alert
12/14/2023Buy Now125.81%Cantor Fitzgerald
Charles Duncan
→ $42ReiteratesOverweight → OverweightGet Alert
12/14/2023Buy Now34.41%Deutsche Bank
Neena Bitritto-Garg
→ $25DowngradeBuy → HoldGet Alert
12/13/2023Buy Now104.3%Citigroup
David Hoang
→ $38Initiates → BuyGet Alert
12/12/2023Buy Now34.41%Deutsche Bank
Neena Bitritto-Garg
→ $25Initiates → BuyGet Alert
11/06/2023Buy Now115.05%Canaccord Genuity
Sumant Kulkarni
$38 → $40MaintainsBuyGet Alert
11/06/2023Buy Now88.17%Mizuho
Uy Ear
$20 → $35UpgradeNeutral → BuyGet Alert
11/03/2023Buy Now125.81%JMP Securities
Jason Butler
$39 → $42MaintainsMarket OutperformGet Alert
11/03/2023Buy Now77.42%RBC Capital
Gregory Renza
$32 → $33MaintainsOutperformGet Alert
11/03/2023Buy Now66.67%Morgan Stanley
Jeffrey Hung
$30 → $31MaintainsEqual-WeightGet Alert
10/17/2023Buy Now77.42%UBS
Ashwani Verma
→ $33Initiates → BuyGet Alert
10/10/2023Buy Now72.04%JP Morgan
Tessa Romero
$29 → $32UpgradeNeutral → OverweightGet Alert
08/22/2023Buy Now125.81%Cantor Fitzgerald
Sarah James
→ $42ReiteratesOverweight → OverweightGet Alert
08/07/2023Buy Now55.91%JP Morgan
Julio Romero
$28 → $29MaintainsNeutralGet Alert
08/03/2023Buy Now104.3%Canaccord Genuity
Sumant Kulkarni
$39 → $38MaintainsBuyGet Alert
08/03/2023Buy Now61.29%Morgan Stanley
Jeffrey Hung
$30 → $30ReiteratesEqual-Weight → Equal-WeightGet Alert
08/03/2023Buy Now34.41%Oppenheimer
Jay Olson
→ $25ReiteratesPerform → PerformGet Alert
08/03/2023Buy Now77.42%HC Wainwright & Co.
Andrew Fein
→ $33ReiteratesBuy → BuyGet Alert
07/28/2023Buy Now34.41%Oppenheimer
Jay Olson
$23 → $25MaintainsPerformGet Alert
07/17/2023Buy Now109.68%Canaccord Genuity
Sumant Kulkarni
$28 → $39MaintainsBuyGet Alert
07/17/2023Buy Now125.81%Cantor Fitzgerald
Sarah James
$36 → $42MaintainsOverweightGet Alert
07/14/2023Buy Now77.42%RBC Capital
Gregory Renza
$28 → $33MaintainsOutperformGet Alert
07/14/2023Buy Now45.16%Citigroup
Neena Bitritto-Garg
$21.6 → $27MaintainsNeutralGet Alert
07/14/2023Buy Now61.29%Morgan Stanley
Jeffrey Hung
$21 → $30MaintainsEqual-WeightGet Alert
07/14/2023Buy Now109.68%JMP Securities
Jason Butler
$31 → $39MaintainsMarket OutperformGet Alert
07/14/2023Buy Now23.66%Oppenheimer
Jay Olson
$20 → $23MaintainsPerformGet Alert
07/14/2023Buy Now77.42%HC Wainwright & Co.
Andrew Fein
$28 → $33MaintainsBuyGet Alert
07/11/2023Buy Now12.9%Morgan Stanley
Jeffrey Hung
$20 → $21MaintainsEqual-WeightGet Alert
06/14/2023Buy Now66.67%JMP Securities
Jason Butler
$23 → $31MaintainsMarket OutperformGet Alert
06/14/2023Buy Now7.53%Mizuho
Uy Ear
→ $20ReiteratesNeutral → NeutralGet Alert
06/14/2023Buy Now50.54%HC Wainwright & Co.
Andrew Fein
→ $28ReiteratesBuy → BuyGet Alert
05/22/2023Buy Now39.78%B of A Securities
Tazeen Ahmad
$23 → $26MaintainsNeutralGet Alert
05/09/2023Buy Now77.42%Cantor Fitzgerald
Sarah James
→ $33Reiterates → OverweightGet Alert
05/09/2023Buy Now45.16%RBC Capital
Gregory Renza
→ $27Reiterates → OutperformGet Alert
05/09/2023Buy Now23.66%JMP Securities
Jason Butler
$22 → $23MaintainsOutperformGet Alert
05/09/2023Buy Now50.54%HC Wainwright & Co.
Andrew Fein
→ $28Reiterates → BuyGet Alert
05/09/2023Buy Now16.13%Citigroup
Neena Bitritto-Garg
$21 → $21.6MaintainsNeutralGet Alert
04/14/2023Buy Now7.53%Mizuho
Uy Ear
→ $20Reiterates → NeutralGet Alert
03/20/2023Buy Now12.9%JP Morgan
Julio Romero
$19 → $21MaintainsNeutralGet Alert
03/14/2023Buy Now23.66%B of A Securities
Tazeen Ahmad
→ $23MaintainsNeutralGet Alert
03/14/2023Buy Now7.53%Morgan Stanley
Jeffrey Hung
$19 → $20MaintainsEqual-WeightGet Alert
03/14/2023Buy Now45.16%RBC Capital
Gregory Renza
→ $27Reiterates → OutperformGet Alert
03/14/2023Buy Now39.78%Canaccord Genuity
Sumant Kulkarni
$24 → $26MaintainsBuyGet Alert
03/14/2023Buy Now77.42%Cantor Fitzgerald
Charles Duncan
$28 → $33MaintainsOverweightGet Alert
03/14/2023Buy Now12.9%Citigroup
Neena Bitritto-Garg
$19.4 → $21MaintainsNeutralGet Alert
03/14/2023Buy Now50.54%HC Wainwright & Co.
Andrew Fein
$25 → $28MaintainsBuyGet Alert
03/13/2023Buy Now2.15%Mizuho
Uy Ear
→ $19Reiterates → NeutralGet Alert
03/01/2023Buy Now7.53%Oppenheimer
Jay Olson
$17 → $20MaintainsPerformGet Alert
02/28/2023Buy Now34.41%HC Wainwright & Co.
Andrew Fein
→ $25Reiterates → BuyGet Alert
02/28/2023Buy Now18.28%JMP Securities
Jason West
$24 → $22MaintainsMarket PerformGet Alert
02/28/2023Buy Now4.3%Citigroup
Neena Bitritto-Garg
$19 → $19.4MaintainsNeutralGet Alert
02/28/2023Buy Now45.16%RBC Capital
Gregory Renza
$19 → $27MaintainsOutperformGet Alert
02/28/2023Buy Now2.15%Morgan Stanley
Jeffrey Hung
$18 → $19MaintainsEqual-WeightGet Alert
02/28/2023Buy Now2.15%Mizuho
Uy Ear
$15 → $19MaintainsNeutralGet Alert
02/15/2023Buy Now-8.6%Oppenheimer
Jay Olson
$16 → $17MaintainsPerformGet Alert
01/31/2023Buy Now2.15%Citigroup
Neena Bitritto-Garg
$17 → $19MaintainsNeutralGet Alert
01/03/2023Buy Now18.28%Guggenheim
Yatin Suneja
→ $22UpgradeNeutral → BuyGet Alert
12/21/2022Buy Now-19.35%Mizuho
Uy Ear
$17 → $15MaintainsNeutralGet Alert
11/14/2022Buy Now-8.6%JP Morgan
Tessa Romero
$19 → $17MaintainsNeutralGet Alert

FAQ

Q

What is the target price for ACADIA Pharmaceuticals (ACAD) stock?

A

The latest price target for ACADIA Pharmaceuticals (NASDAQ:ACAD) was reported by Morgan Stanley on July 12, 2024. The analyst firm set a price target for $28.00 expecting ACAD to rise to within 12 months (a possible 50.54% upside). 60 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ACADIA Pharmaceuticals (ACAD)?

A

The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) was provided by Morgan Stanley, and ACADIA Pharmaceuticals maintained their overweight rating.

Q

When was the last upgrade for ACADIA Pharmaceuticals (ACAD)?

A

The last upgrade for ACADIA Pharmaceuticals Inc happened on January 24, 2024 when Needham raised their price target to $37. Needham previously had a hold for ACADIA Pharmaceuticals Inc.

Q

When was the last downgrade for ACADIA Pharmaceuticals (ACAD)?

A

The last downgrade for ACADIA Pharmaceuticals Inc happened on March 12, 2024 when Mizuho changed their price target from $39 to $25 for ACADIA Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for ACADIA Pharmaceuticals (ACAD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.

Q

Is the Analyst Rating ACADIA Pharmaceuticals (ACAD) correct?

A

While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a maintained with a price target of $30.00 to $28.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $18.60, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch